Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Elemento
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicaciónTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Título
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Materia
Descripción
With more than 81 000 deaths worldwide from coronavirus disease 2019 (COVID-19) by April 8, 2020, it is incumbent on researchers to accelerate clinical trials of any readily available and potentially acceptably safe therapies that could reduce the rising death toll.
Fecha
2020-04-09
Tipo
Citación
Feldmann, Marc, Ravinder N. Maini, James N. Woody, Stephen T. Holgate, Gregory Winter, Matthew Rowland, Duncan Richards, and Tracy Hussell. 2020. "Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed." The Lancet 395 (10234):1407-9.
Accesibilidad
Free online on Lancet site
Was this resource helpful?